Pharmacogenetic testing for adverse drug reaction prevention: systematic review of economic evaluations and the appraisal of quality matters for clinical practice and implementation

被引：0
作者：
Saowalak Turongkaravee
Jiraphun Jittikoon
Onwipa Rochanathimoke
Kathleen Boyd
Olivia Wu
Usa Chaikledkaew
机构：
[1] Mahidol University,Social, Economic and Administrative Pharmacy (SEAP) Graduate Program, Department of Pharmacy, Faculty of Pharmacy
[2] Mahidol University,Department of Biochemistry, Faculty of Pharmacy
[3] Institute of Health and Wellbeing,Health Economics and Health Technology Assessment (HEHTA)
[4] University of Glasgow,Social and Administrative Pharmacy Division, Department of Pharmacy, Faculty of Pharmacy
[5] Mahidol University,undefined
[6] Mahidol University Health Technology Assessment (MUHTA) Graduate Program,undefined
[7] Mahidol University,undefined
来源：
BMC Health Services Research | / 21卷
关键词：
Pharmacogenomics; Adverse drug reactions; Economic-evaluation; Systematic review; Personalized medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 541 条
  • [31] Hughes DA(2014)Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome Ann Intern Med 160 221-2021
  • [32] Cooper N(2013)Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia Pharmacogenomics. 14 2013-91
  • [33] Coyle D(2013)Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis J Thromb Haemost 11 81-332
  • [34] Abrams K(2012)Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel Pharmacotherapy. 32 323-1084
  • [35] Mugford M(2012)The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation Pharmacoeconomics. 30 1067-105
  • [36] Sutton A(2017)Economic evaluation of a pharmacogenomics test for statin-induced myopathy in cardiovascular high-risk patients initiating a statin Mol Diagn Ther 21 95-67
  • [37] Moher D(2018)Cost-effectiveness analysis of HLA-B*58: 01 genetic testing before initiation of allopurinol therapy to prevent allopurinol-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a Malaysian population Pharmacogenet Genomics 28 56-124
  • [38] Liberati A(2018)A retrospective investigation of HLA-B*5801 in hyperuricemia patients in a Han population of China Pharmacogenet Genomics 28 117-1739
  • [39] Tetzlaff J(2017)Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout Rheumatology (Oxford) 56 1729-843
  • [40] Altman DG(2017)Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions J Rheumatol 44 835-600
12345678910